AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV)

Today's Latest Price: $100.48 USD

1.61 (1.63%)

Updated Jul 15 6:40pm

Add ABBV to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABBV Stock Summary

  • ABBV has a market capitalization of $148,383,057,763 -- more than approximately 98.92% of US stocks.
  • The capital turnover (annual revenue relative to shareholder's equity) for ABBV is -4.59 -- better than only 3.21% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -9.17 for AbbVie Inc; that's greater than it is for just 2.2% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AbbVie Inc are AMGN, AZN, NVO, BMY, and LLY.
  • Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to
ABBV Daily Price Range
ABBV 52-Week Price Range

ABBV Stock Price Chart Technical Analysis Charts

ABBV Price/Volume Stats

Current price $100.48 52-week high $100.69
Prev. close $98.87 52-week low $62.55
Day low $98.82 Volume 5,661,600
Day high $100.48 Avg. volume 11,071,702
50-day MA $93.68 Dividend yield 4.7%
200-day MA $86.02 Market Cap 148.38B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for ABBV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that AbbVie Inc ranked in the 67th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 155.5% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of AbbVie Inc, consider:

  • The company's balance sheet shows it gets 69% of its capital from equity, and 31% of its capital from debt. Its equity weight surpasses that of merely 23.64% of free cash flow generating stocks in the Healthcare sector.
  • AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 11.31% of tickers in our DCF set.
  • ABBV's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 11.31% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of AbbVie Inc? See MCK, NVO, CHE, PCRX, and DVA.

ABBV Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

CATH: What The 'Catholic S&P 500' ETF Excludes Vs. Overweights

Judging by the percentage of assets in faith-based ETFs, relative to the percentages of Americans who are religiously observant, it seems obvious that a large percentage of even relatively religious Americans do not see the need to limit their ETF purchases to those aligning with their religious beliefs. While I...

Tariq Dennison on Seeking Alpha | July 15, 2020

Researchers Say AbbVie's Tricor Reduced Severity Of COVID-19 Into 'Nothing Worse Than A Common Cold'

AbbVie Inc (NYSE: ABBV) shares popped Tuesday after researchers found that the large-cap pharma's cholesterol-lowering drug Tricor could work against SARS-CoV2, the virus that causes COVID-19.What Happened: Researchers at Israel's Hebrew University and the Mount Sinai Medical Center in New York said FDA-approved Tricor could potentially downgrade COVID-19's severity into "nothing worse than a common cold," Israeli media reported.Tricor impairs the replicating potential of the new coronavirus or even could eradicate it, the reports said, citing Hebrew University professor Ya'acov Nahmias and Sinai's Dr. Benjamin tenOever.See Also: Moderna's Stock Jumps After Coronavirus Vaccine Shows Positive Results In Phase 1 Clinical TrialHow Tricor Acts: Following ...

Yahoo | July 15, 2020

Investing legend Bill Gross says investors should favor value over growth during the pandemic, and tipped these 4 stocks to flourish

Legendary investor Bill Gross said investors should look more closely at value stocks rather than growth stocks like Apple, Netflix, and Amazon to make money right now. The retired fund manager said in his first investment outlook of the coronavirus pandemic that the outperformance of the "Fab 5" technology companies and other growth stocks are linked to real interest rates. Gross named four value stocks — IBM, Altria, Enterprise Products, and Abbvie — that he backs right now. "Value stocks, versus growth stocks, should be an investor's preference in the near-term future," he wrote Visit Business Insider's homepage for more stories . Legendary investor Bill Gross, who is currently chairman of California-based tech incubator IdeaLab, said on Tuesday that investors should choose value sto...

Business Insider | July 14, 2020

New Products, Expanded Indications Drive Sales of Top 5 Pharmas

Some companies may turn to acquisitions to boost revenues Continue reading...

Yahoo | July 14, 2020

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $98.87, moving +1.03% from the previous trading session.

Yahoo | July 14, 2020

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo 5.88%
3-mo 21.88%
6-mo 17.30%
1-year 55.36%
3-year 59.07%
5-year 78.27%
YTD 18.16%
2019 1.47%
2018 -0.96%
2017 60.07%
2016 9.79%
2015 -6.50%

ABBV Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.954 seconds.